Aptevo Therapeutics Inc

This proposal asks shareholders to cast a non-binding advisory vote to approve the Company’s disclosed 2025 named executive officer compensation (the Say-on-Pay vote). Management is seeking this advisory approval to confirm alignment between executive pay and stockholder interests and to respond to stockholder preferences regarding executive compensation disclosure and governance. The vote is explicitly non-binding; however, the Board and Compensation Committee state they will review the results and consider them when setting future compensation. The Company indicates its compensation mix emphasizes equity awards to align long-term incentives, and the Compensation Committee retained an independent consultant (Willis Towers Watson) to benchmark pay practices and target competitive percentiles. The Board recommends a "FOR" vote, arguing that the 2025 compensation program reflects challenging corporate goals, appropriate pay-for-performance features, and steps (including supplemental cash payments in 2025) taken to remain competitive given share constraints. Because the vote is advisory, approval does not change existing awards or contracts, but a negative result would likely trigger engagement and reconsideration of pay program design. The proposal's governance context includes the Company’s adoption of a compensation recovery policy and stock ownership guidelines to further align executives with stockholders. Given Aptevo’s early-stage profile and reliance on equity to attract and retain talent, the Say-on-Pay vote functions as a key feedback mechanism rather than an enforceable mandate. Analysts should weigh the advisory outcome as an indicator of shareowner sentiment toward compensation practices and potential adjustments by the Board, particularly in light of subsequent equity plan amendments and burn-rate considerations.

This proposal requests shareholder approval to amend and restate the Company’s equity incentive plan to add 145,000 shares to the existing share reserve, representing a material increase in the capacity to grant equity awards. Management frames the request as necessary to continue issuing equity-based awards that align employee and director interests with stockholders, support retention, and avoid raising cash compensation that would strain resources. The Fourth Amended Plan incorporates governance-oriented features: prohibition on discounted options and SARs, no liberal share recycling, minimum one-year vesting (with limited exceptions), clawback provisions tied to restatements and misconduct, limits on director award value, and anti-repricing protections. The filing provides quantitative context — a dilution/overhang analysis showing overhang rising from 0.59% to 6.77% if the new shares are included, and a historical burn-rate analysis showing a three-year average VABR of 10.80% — which informs potential dilution and expected longevity of the reserve (management estimates the increase would meet grant needs through December 31, 2026 under current assumptions). The Board recommends a "FOR" vote, asserting the share increase is reasonable given hiring plans, historical usage, and inducement grants, while pointing to the plan’s governance safeguards intended to limit abuse and reduce unwelcome dilution. Key risks for investors include the incremental dilution, potential for accelerated grant pace if the stock is used heavily for retention or hiring, and the concentration of benefits among executives and directors who are eligible recipients. Analysts should weigh the trade-off between the company’s operational need to grant equity in a competitive labor market against the modest additional dilution and evaluate whether the plan’s anti-dilution and governance provisions sufficiently protect long-term shareholder value.